Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Breast cancer Patients' vision under the microscope

NCT ID NCT06767462

Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study checks the eye health of people with breast cancer using standard tests like vision charts, eye exams, and scans. The goal is to spot any vision changes or eye damage that might happen during cancer treatment. About 160 participants will be followed to understand how breast cancer and its treatments affect the eyes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors monitor and protect vision in breast cancer patients during treatment.
What could go wrong
This is an observational safety study, not a treatment trial. It may not lead to direct changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 160 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients who are currently participating in qualifying studies

Ages

18 to 130 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Signed informed consent in the qualifying study. 2. Signed informed consent in the ophthalmic study prior to any ophthalmic study specific assessments and procedures. 3. Completed the baseline ophthalmic examination for this study before the first dose in the qualifying study. 4. Meets all the eligibility criteria in the qualifying study Exclusion Criteria: 1. Patients not randomized and not receiving study assigned treatment in a qualifying study. 2. Patients with contraindications to any ophthalmic procedure required by the study or sensitivity/allergy to pupil dilating agents. 3. Judgement by the investigator that the patient should not participate in the ophthalmic study if the patient is unlikely to comply with study procedures, restrictions, and requirements

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ophthalmic safety in patients with breast cancer

Contacts and locations

Locations

  • Research Site

    La Jolla, California, 92093, United States

  • Research Site

    Palo Alto, California, 94304, United States

  • Research Site

    Iowa City, Iowa, 52242, United States

  • Research Site

    Winston-Salem, North Carolina, 27104, United States

  • Research Site

    Clairton, Pennsylvania, 15025, United States

  • Research Site

    Pittsburgh, Pennsylvania, 15219, United States

  • Research Site

    Sioux Falls, South Dakota, 57105, United States

  • Research Site

    Bartlett, Tennessee, 38133, United States

  • Research Site

    Houston, Texas, 77030, United States

  • Research Site

    CABA, C1061, Argentina

  • Research Site

    Córdoba, 5008, Argentina

  • Research Site

    Leuven, 3000, Belgium

  • Research Site

    Liège, 4000, Belgium

  • Research Site

    Alfenas, 37130-000, Brazil

  • Research Site

    Belo Horizonte, 30130-100, Brazil

  • Research Site

    Curitiba, 80810-050, Brazil

  • Research Site

    Lajeado, 95900000, Brazil

  • Research Site

    Porto Alegre, 90050-170, Brazil

  • Research Site

    Pouso Alegre, 37554-216, Brazil

  • Research Site

    São Paulo, 01321-001, Brazil

  • Research Site

    Sorocaba, 18060-105, Brazil

  • Research Site

    Três Lagoas, 79601-001, Brazil

  • Research Site

    Vitória, 29055-450, Brazil

  • Research Site

    Montreal, Quebec, H2X 3E4, Canada

  • Research Site

    Montreal, Quebec, H4A 3J1, Canada

  • Research Site

    Santiago, 7500587, Chile

  • Research Site

    Santiago, 7620157, Chile

  • Research Site

    Ashdod, 7747629, Israel

  • Research Site

    Nahariya, 2210001, Israel

  • Research Site

    Lodz, 90-302, Poland

  • Research Site

    Amadora, 2720-276, Portugal

  • Research Site

    Braga, 4710-243, Portugal

  • Research Site

    Seoul, 6351, South Korea

  • Research Site

    Badalona, 08003, Spain

  • Research Site

    Barcelona, 08028, Spain

  • Research Site

    Barcelona, 08035, Spain

  • Research Site

    Barcelona, 08036, Spain

  • Research Site

    Girona, 17007, Spain

  • Research Site

    L'Hospitalet de Llobregat, 08908, Spain

  • Research Site

    Leganés, 28911, Spain

  • Research Site

    Madrid, 28007, Spain

  • Research Site

    Madrid, 28009, Spain

  • Research Site

    Madrid, 28033, Spain

  • Research Site

    Madrid, 28034, Spain

  • Research Site

    Madrid, 28040, Spain

  • Research Site

    Madrid, 28041, Spain

  • Research Site

    Madrid, 28050, Spain

  • Research Site

    Majadahonda, 28222, Spain

  • Research Site

    Salamanca, 37007, Spain

  • Research Site

    Sant Joan Despí, 08970, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.